Skip to main content
. 2020 Jul 27;10(9):1802–1809. doi: 10.1002/2211-5463.12930

Fig. 3.

Fig. 3

The serum LINC00887 signature may serve as a non‐invasive biomarker for the detection of early‐stage RCC and is associated with RCC patient survival. (A) ROC curve shows an AUC of serum LINC00887 signature with respect to differentiating RCC patients from healthy subjects, with a sensitivity of 67.09% and a specificity of 89.87%. (B) ROC curve shows an AUC of the serum LINC00887 signature with respect to differentiating T1/T2‐stage RCC patients from healthy subjects, with a sensitivity of 71.05% and a specificity of 89.87%. (C) ROC curve shows an AUC of serum LINC00887 signature with respect to comparing non‐metastatic RCC patients with healthy subjects, with a sensitivity of 73.33% and a specificity of 89.87%. (D) Overall survival analysis reveals RCC patients with a high expression of LINC00887 in serum have worse survival rates compared to those with low expression.